GT Biopharma reduces stockholder meeting quorum from majority to one-third

GT Biopharma, Inc.

Board approved amendment to bylaws effective June 8, 2026.
Quorum lowered from majority to not less than one-third of outstanding voting shares.
Change aims to improve meeting attendance amid broker non-voting trends.
Company is fully remote as of July 1, 2024; no principal executive office.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

GT Biopharma, Inc.: Reduced quorum requirement for stockholder meetings from a majority to not less than one-third of outstanding shares entitled to vote (effective 2026-06-08).

Change: bylaw amendment
Effective: 2026-06-08

Exact text from the filing

On June 8, 2026, the Board of Directors (the “Board”) of GT Biopharma, Inc., a Delaware corporation (the “Company”) approved an amendment (the “Amendment”) to the Company’s Amended and Restated Bylaws, effective June 8, 2026, to reduce the number of shares that are required to be present in person or by proxy at a meeting of the Company’s stockholders (a “Meeting”) for purposes of establishing a quorum.

View on SEC.gov

Browse all governance changes →

GT Biopharma, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-26-028457

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.